Bradley Pharmaceuticals Inc announced that an agreement has been signed with Ventiv Health Inc, to co-promote AnaMantle HC, a unique hemorrhoid therapy with a clean, neat, disposable delivery system. AnaMantle HC was introduced to gastroenterologists and colorectal surgeons by Bradley's Kenwood Therapeutics division in January 2002, and is now one of the Company's fastest growing brands. As of July 14, 2003, Ventiv Health's existing VenFemme sales division of 30 sales representatives began to promote AnaMantle HC to OB/GYN physicians. By partnering with Ventiv Health, Bradley has expanded into an additional target physician specialty audience with a full, experienced sales force.
Bradley Vice President, General Manager of Kenwood Therapeutics, Jurgen van den Woldenberg, stated, "Bradley is pleased to partner with Ventiv Health Inc, and to support VenFemme's sales staff with Bradley print promotion and mail sample distribution. Currently, the OB/GYN specialty market accounts for approximately 300,000 new prescriptions for hemorrhoid treatments annually."
President of Ventiv Health US Sales, Terry Herring, stated, "Ventiv believes that the VenFemme rapport with OB/GYN audiences combined with AnaMantle HC therapeutic benefits will provide the opportunity for synergistic growth for both companies."